RLMD - Enrollment underway in Relmada Therapeutics' late-stage depression study with REL-1017

Relmada Therapeutics ([[RLMD]] -2.1%) has enrolled first patient in first Phase 3 trial (RELIANCE I) evaluating its lead product candidate, REL-1017, as an adjunctive treatment for major depressive disorder. Topline data is expected in 1H of 2022.Primary endpoint will be the change from baseline on the depression rating scale score at day-28 compared to placebo.The Company expects to initiate a second Phase 3 trial, RELIANCE II, in 1H of 2021, and patients who complete RELIANCE I and RELIANCE II will be eligible to rollover into the long-term, open-label study, which is also expected to include subjects who had not previously participated in a REL-1017 trial.

For further details see:

Enrollment underway in Relmada Therapeutics' late-stage depression study with REL-1017